Autologous hematopoietic stem cell transplantation in a patient with multi-refractory stiff person syndrome
Tamim Alsuliman,Dimitri Psimaras,Nicolas Stocker,Simona Sestili,Anne Banet,Zoé Van de Wyngaert,Agnès Bonnin,Manuela Badoglio,Mathieu Puyade,Dominique Farge,Mohamad Mohty,Zora Marjanovic
DOI: https://doi.org/10.1038/s41409-024-02440-x
2024-10-19
Bone Marrow Transplantation
Abstract:Stiff person syndrome (SPS) is a rare neurological autoimmune disease (AD) with a prevalence of 1-2 patients per million, predominantly observed in women (2-3 females:1 man) [1, 2]. It is characterized by progressive stiffness of skeletal muscles, episodic painful muscle spasms, and prevention of volitional movements and ambulation in severe cases. Lumbar para-spinal rigidity limits the range of body mobility. Spasms due to increased muscle stiffness occur spontaneously or secondarily to different external and internal stimuli [1, 2]. Recent progress in the understanding of SPS pathophysiology support the predominant theory based on the immune-mediated interference of inhibitory signaling leading to nervous system hyperexcitability [1, 2]. It is a widely accepted hypothesis that an inhibitory effect on glutamic acid decarboxylase (GAD65) by anti-GAD65 antibodies blocks gamma-aminobutyric acid (GABA) synthesis and reduces the uptake of GABA in synaptic vesicles and thereby synaptic GABA release. Decreased synthesis of GABA results in decreased GABAergic transmission, leading to a state of neuronal hyperexcitability [3]. On the other hand, the autoantibody anti-glycine receptor alpha-1 subunit (GlyRα1) binds directly to motor neurons in the spinal cord and brainstem leading to motor neuron hyperactivity. This proposed mechanism was further supported by the demonstration that ...human GlyR-immunoglobulin G (IgG), which disrupts inhibitory neurotransmission in cultured rodent motor neurons showing direct antagonistic actions on the glycine receptor [4]. However, the exact pathological role of anti-GAD and anti-GlyRα1 in humans is unknown, and different associated antibodies (anti-amphiphysin, dipeptidyl peptidase-like protein 6 (DPPX) and gephyrin) likely reflect different underlying pathophysiologic mechanisms [3]. It has also been suggested that GlyRα1-positive SPS may be more immunotherapy-responsive compared with patients with GAD65-positive SPS [5].
oncology,immunology,hematology,transplantation